Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Artrya Limited ( (AU:AYA) ).
Artrya Limited reported a 17.2% increase in its annual loss, amounting to $16.4 million for the year ended June 30, 2025, compared to the previous year. Despite the financial setback, the company’s net tangible assets per ordinary security saw a slight increase, reflecting a potential for stability in its asset management.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$2.87 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
More about Artrya Limited
Artrya Limited operates in the healthcare industry, focusing on developing innovative medical technology solutions. The company specializes in creating software for the detection of coronary artery disease, aiming to improve diagnostic accuracy and patient outcomes.
Average Trading Volume: 266,373
Technical Sentiment Signal: Buy
For detailed information about AYA stock, go to TipRanks’ Stock Analysis page.